Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oncolytics Biotech Inc. - Common Shares (TSX: ONC ) 1.410 +0.120 (+9.30%) Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 199,488 Open 1.350 Bid (Size) 1.390 (2) Ask (Size) 1.410 (116) Prev. Close 1.290 Today's Range 1.280 - 1.420 52wk Range 1.020 - 2.080 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses December 20, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence COVID-19 Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers December 18, 2024 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END Via FinancialNewsMedia Performance YTD -19.89% -19.89% 1 Month +7.63% +7.63% 3 Month +15.57% +15.57% 6 Month +2.92% +2.92% 1 Year -12.42% -12.42% More News Read More Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers December 18, 2024 From FN Media Group LLC Via GlobeNewswire Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium December 18, 2024 Via FinancialNewsMedia Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket October 04, 2024 Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study September 20, 2024 Via FinancialNewsMedia Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 Via FinancialNewsMedia How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs September 20, 2024 Via FinancialNewsMedia Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer June 20, 2024 Via FinancialNewsMedia Exposures Product Safety How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs September 20, 2024 From FN Media Group LLC Via GlobeNewswire Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth June 20, 2024 Via FinancialNewsMedia Topics Death Exposures Death Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 May 24, 2024 Via FinancialNewsMedia Topics Death Exposures Death Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth June 20, 2024 From FN Media Group LLC Via GlobeNewswire Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action May 24, 2024 Via FinancialNewsMedia Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 June 20, 2024 From FN Media Group LLC Via GlobeNewswire Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 May 09, 2024 Via FinancialNewsMedia Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 May 24, 2024 From FN Media Group LLC Via GlobeNewswire Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer May 09, 2024 Via FinancialNewsMedia Biotech Innovations Paving the Way in Breast Cancer Fight April 11, 2024 Via FinancialNewsMedia Topics Death Exposures Death Product Safety Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA April 11, 2024 Via FinancialNewsMedia Exposures Product Safety Biotech’s Role in Addressing the Pancreatic Cancer Emergency March 14, 2024 Via FinancialNewsMedia Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth March 06, 2024 Via FinancialNewsMedia Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning March 06, 2024 Via Newsfile Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments March 05, 2024 Via FinancialNewsMedia Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments March 05, 2024 From FN Media Group LLC Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
